US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
pharma · Asthma · Pharmacokinetics · AMPH
Amphastar France Pharmaceuticals
Amphastar France Pharmaceuticals drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
USINE SAINT CHARLES, ERAGNY SUR EPTE, 60590, FR, Rancho Cucamonga HQ
1996 Founded
46 Employees
Public company Type
AMPH · NYSE Ticker
Company details
- Status
- Public
- HQ
- USINE SAINT CHARLES, ERAGNY SUR EPTE, 60590, FR, Rancho Cucamonga
- Founded
- 1996
- Employees
- 46
- Programs
- 18
- Drugs
- 15
- Patents
- 15
Amphastar France Pharmaceuticals pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Amphastar France Pharmaceuticals drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: Adrenocorticotropic hormone receptor.
- Target
- Adrenocorticotropic hormone receptor
- Mechanism
- Melanocortin receptor 2 agonist
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
glucagon
Systemic hormonal preparations (H04)US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
US regulatory status: approved. Molecular target: Hyaluronic acid.
- Target
- Hyaluronic acid
- Mechanism
- Hyaluronic acid hydrolytic enzyme
-
Development asset linked to Amphastar France Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Amphastar France Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Amphastar France Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Amphastar France Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Amphastar France Pharmaceuticals in public FDA and regional records.